Promising clinical outcomes of nano‐curcumin treatment as an adjunct therapy in hospitalized COVID‐19 patients: A randomized, double‐blinded, placebo‐controlled trial

Author:

Sadeghizadeh Majid1ORCID,Asadollahi Elahe1,Jahangiri Babak12,Yadollahzadeh Mahdi3,Mohajeri Maryam4,Afsharpad Mandana5,Najafi Farhood6,Rezaie Nader7,Eskandari Mohana3,Tavakoli‐Ardakani Maria8,Feizabadi Faezeh8,Masjedi Mohammad Reza5910

Affiliation:

1. Department of Genetics, Faculty of Biological Sciences Tarbiat Modares University Tehran Iran

2. Department of Molecular Medicine, Institute of Medical Biotechnology National Institute of Genetic Engineering and Biotechnology (NIGEB) Tehran Iran

3. Firoozgar Medical & Educational Hospital Department of Internal Medicine School of Medicine Iran University of Medical Sciences Tehran Iran

4. Alborz Nanomed Tech Company Tehran Iran

5. Cancer Control Research Center, Cancer Control Foundation Iran University of Medical Sciences Tehran Iran

6. Department of Resin and Additives Institute for Color Science and Technology Tehran Iran

7. Department of Pulmonology Firouzgar Hospital, Iran University of Medical Sciences Tehran Iran

8. Department of Clinical Pharmacy School of Pharmacy, Shahid Beheshti University of Medical Sciences Tehran Iran

9. Department of Pulmonary Medicine Shahid Beheshti University of Medical Sciences Tehran Iran

10. Tobacco Control Research Center (TCRC) Iranian Anti‐tobacco Association, Iran University of Medical Sciences Tehran Iran

Abstract

AbstractDifferent immunomodulation strategies have been used to manage COVID‐19 due to the complex immune‐inflammatory processes involved in the pathogenesis of this infection. Curcumin with its powerful anti‐inflammatory and antiviral properties could serve as a possible COVID‐19 therapy. In this study, a randomized, double‐blinded, placebo‐controlled trial was performed to investigate the effectiveness and safety of nano‐curcumin oral soft gels as a complementary therapy in moderate–severe COVID‐19 patients. Hydroxychloroquine (HCQ) plus sofosbuvir was routinely administered to all 42 COVID‐19 patients, who were randomly assigned to receive 140 mg of nano‐curcumin or placebo for 14 days. CT scans of the chest were taken, and blood tests were run for all patients at time points of 0, 7, and 14 days. Our results indicated that C‐reactive protein (CRP) and erythrocyte sedimentation rate (ESR) levels significantly decreased from baseline in the nano‐curcumin‐treated group on day 7. Furthermore, blood levels of D‐dimer, CRP, serum ferritin, ESR, and inflammatory cytokines including IL‐6, IL‐8, and IL‐10 decreased more significantly in the nano‐curcumin‐treated group after 14 days. Additionally, the nano‐curcumin group showed significant improvements in chest CT scores, oxygen saturation levels, and hospitalization duration. Based on our data, oral administration of nano‐curcumin may be regarded as a promising adjunct treatment for COVID‐19 patients due to its ability to speed up chest clearance and recovery.

Funder

National Institute for Genetic Engineering and Biotechnology

Publisher

Wiley

Subject

Pharmacology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3